Bicuspid/Mitral Heart Failure Open-Heart Surgery 
DAIC
JUNE 3, 2024
milla1cf Mon, 06/03/2024 - 12:36 June 3, 2024 — HighLife SAS , a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe Mitral Regurgitation (MR), announced today that the U.S. I am honored to lead the HighLife pivotal study.
DAIC
FEBRUARY 21, 2024
Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. director of Interventional and Structural Heart Research at Henry Ford Hospital.
DAIC
FEBRUARY 20, 2024
The Intrepid TMVR is a heart valve that is designed to help alleviate mitral regurgitation so that blood can flow through the heart in the intended direction,” said Matthew Saybolt , M.D., FACC, principal site investigator and medical director, Structural Heart Disease Program, Jersey Shore University Medical Center.
DAIC
FEBRUARY 15, 2024
Delivered through a vein in the leg, TriClip's TEER technology works by clipping together a portion of the leaflets – or flaps of tissue – to repair the tricuspid valve and help blood flow in the right direction without the need for open-heart surgery.
DAIC
APRIL 2, 2024
Sorajja added, "With TriClip, physicians can offer patients a therapy option backed by excellent safety and effectiveness to help restore tricuspid native valve performance without subjecting them to high-risk open-heart surgery that may not be feasible for individuals with TR who are generally older and sicker."
Expert insights. Personalized for you.
105 
Let's personalize your content